Eli Casdin
InvestorChief Investment Officer and Founder at Casdin Capital
New York, New York
Writes $100K – $5M checks · typically $1.5M
About
Eli Casdin authored mid-2000s roadmap The Dawn of Molecular Medicine and backs platforms using biological data as decision-making infrastructure while guiding companies to markets via co‑sponsored CM Life Sciences SPACs.
Invests in
AgTechBiotechData & InfrastructureFoodTechHealthtechMedical Devices
Experience
- Casdin Capital, LLCChief Investment Officercurrent2011 — presentGreater New York City Area
- The Rockefeller UniversityBoard Membercurrent2021 — present
- New York Genome CenterBoard Membercurrent2020 — presentNew York, United States
- Columbia University School of General StudiesMember, Board of Visitorscurrent2015 — present
- Standard BioToolsBoard Membercurrent2022 — present
- GeneDxBoard Membercurrent2020 — present
- Prominex Inc.Board Membercurrent2018 — presentSan Diego, California
- GenomaticaBoard Membercurrent2018 — present
- SomaLogicBoard Member2020 — 2024
- Tenaya TherapeuticsBoard Member2019 — 2022
- EQRxBoard Member2020 — 2022
- Exact SciencesBoard Of Directors2017 — 2020Madison, Wisconsin
- Relay TherapeuticsBoard Observer2017 — 2019Cambridge, Massachusetts
- Magenta TherapeuticsBoard Observer2018 — 2019Cambridge, Massachusetts
- Fulcrum TherapeuticsBoard Observer2018 — 2019Cambridge, Ma
- InvitaeBoard Observer2013 — 2015
- SynapDxBoard Observer2013 — 2015
- Alliance BernsteinAnalyst2007 — 2011
- Bear StearnsAssociate2007
- Cooper Hill PartnersAnalyst2003 — 2006
Education
- Columbia Business SchoolMBA, Finance - Accounting2002 — 2003
- Columbia UniversityBachelor of Science2001 — 2003
- University of Vermont1991 — 1993
- Riverdale Country School1987 — 1991
Same school
Also attended Columbia Business School576
+ 570 more
Also attended Columbia University498
+ 492 more
Shared employers
Also worked at GeneDx1
Also worked at Relay Therapeutics9
+ 3 more
Also worked at Magenta Therapeutics2
Also worked at Fulcrum Therapeutics2
Deals · 8
PAIGE.AI, Inc.Board seat
via Casdin Capital · filed Mar 2023 · $39M raise
Cedilla Therapeutics, Inc.Board seat
via Casdin Capital · filed Oct 2021 · $82.6M raise
GenomaticaBoard seat
via Casdin Capital · filed Aug 2021 · $119.1M raise
C2i Genomics, Inc.Board seat
via Casdin Capital · filed Apr 2021 · $100M raise
AbsciBoard seat
via Casdin Capital · filed Mar 2021 · $125M raise
Century Therapeutics, Inc.Board seat
via Casdin Capital · filed Mar 2021 · $160M raise
SOMALOGIC, INCBoard seat
via Casdin Capital · filed Jan 2021 · $250M raise
Vitruvian NetworksBoard seat
via Casdin Capital · filed Nov 2020 · $75M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at Casdin Capital
Network6
Investors connected to Eli in public investor directories — a warm-intro map.
































